BiBBInstruments (BIBB) Q1 2026 earnings summary

Executive summary

• EndoDrill® GI officially launched in the US, with initial sales and clinical use at leading hospitals, and preparations underway for European market entry.

• Positive clinical results for EndoDrill® GI presented at major conferences, demonstrating strong diagnostic utility and safety.

• Financing round completed in April 2026, raising approximately 41.9 MSEK before costs, supporting expansion and product development.

• Production scaling up with new contract manufacturer to meet anticipated demand in the US and Europe.

Financial highlights

• Net sales for Q1 2026 reached 114 KSEK, up from 39 KSEK in Q1 2025.

• Operating loss widened to -4,796 KSEK from -2,862 KSEK year-over-year, mainly due to expensing of previously capitalized development costs.

• Cash and cash equivalents at quarter-end were 2,720 KSEK, down from 19,435 KSEK a year earlier.

• Equity at quarter-end was 32,837 KSEK, compared to 47,770 KSEK in Q1 2025.

• Solidity was 91.8%, down from 95.5% year-over-year.

Outlook and guidance

• Raised capital is expected to finance operations for approximately two years, enabling continued US expansion, European launch, and development of EndoDrill® EBUS for lung cancer.

• Broader US rollout and first European distribution agreement targeted for 2026.

• Initial clinical introduction of EndoDrill® EBUS in Europe planned for 2026, with US regulatory submission to follow.